Molecular Epidemiology of Parkinson's Disease

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2002 by National Institute of Environmental Health Sciences (NIEHS).
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Institute of Environmental Health Sciences (NIEHS)
ClinicalTrials.gov Identifier:
NCT00042107
First received: July 24, 2002
Last updated: July 28, 2010
Last verified: July 2002
  Purpose

The aim of this research is to discover genes which modify risk for Parkinson's disease. The study includes 800 patients with Parkinson's disease, and their estimated 1,222 available siblings. Common variations of at least 9 genes will be studied, including genes associated with personality, substance use, and anxiety and depression.


Condition
Parkinson Disease

Study Type: Observational

Resource links provided by NLM:


Further study details as provided by National Institute of Environmental Health Sciences (NIEHS):

Estimated Enrollment: 2022
Study Start Date: September 2000
Estimated Study Completion Date: June 2005
Detailed Description:

Parkinson's disease (PD) is a common and disabling condition in the expanding elderly population of the US and worldwide. Its etiology remains unknown and both genetic and environmental factors have been suspected. The long-term goal of the proposed studies is to clarify the etiology of PD and to identify means to prevent it. Specifically, we will study the association of PD with susceptibility genes previously found associated with novelty seeking behavior, substance use (tobacco, alcohol, and caffeine), and anxiety and depressive disorders. The hypotheses tested derive directly from our current work and preliminary findings. We will employ the case-unaffected sibling control study design and analyses will use a generalization of the sibling transmission dysequilibrium test, or "S-TDT". In total, nine candidate susceptibility genes will be considered, of which only five have undergone limited study for PD. The candidate susceptibility genes include three detoxification genes, three dopaminergic genes, and three serotonergic genes. We will include 800 cases of PD referred to the Mayo Clinic from a 120-mile radius or from a 5-state region during approximately a 10-year period. We will also include their eligible siblings age 40 years or above, projecting that blood DNA samples will be available for 563 affected probands or siblings and 1,180 unaffected siblings stratified in 521 informative sibships. Sibships with multiple affected or unaffected siblings will be included. PD cases will undergo a clinical assessment and blood sampling, and provide family information through a face-to-face interview followed by a written mail-in form. All living siblings ages 40 and above will be screened for PD using a validated telephone instrument. Subjects screening negative for PD will provide DNA with mail-in blood sampling kits only. Persons screening positive will be clinically assessed at the Mayo Clinic or at home, and blood DNA samples will be directly obtained. Genotyping will be performed using polymerase chain reaction methods and will be blinded to affected or unaffected status. The study will avoid population stratification bias by using sibling controls. The candidate susceptibility genes selected for primary analyses relate to personality traits, substance use, and psychiatric diseases that we have found associated with PD. The selection of these genes represents a major paradigm shift. We will also establish a large DNA bank for rapid and efficient testing of new genetic hypothesis for PD. This application is submitted in response to RFA ES-00-002 ("The Role of the Environment in Parkinson's Disease"). We specifically address the RFA's objectives of evaluating endogenous (including biomarkers) and exogenous (including dietary and lifestyle) susceptibility factors for PD using molecular epidemiology tools.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Patients with Parkinson's disease recruited from the Department of Neurology, Mayo Clinic, Rochester MN, residing in MN or the surrounding 4 states (WI, IA, SD, ND); their siblings above age 40.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00042107

Locations
United States, Minnesota
Department of Neurology, Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Demetrius M Maraganore, MD    507-280-8717    dmaraganore@mayo.edu   
Contact: Walter A Rocca, MD, MPH    507 280 8717    rocca@mayo.edu   
Principal Investigator: Demetrius M Maraganore, MD         
Sponsors and Collaborators
Investigators
Principal Investigator: Demetrius M Maraganore, MD Department of Neurology, Mayo Clinic Rochester
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00042107     History of Changes
Other Study ID Numbers: 10751-CP-001
Study First Received: July 24, 2002
Last Updated: July 28, 2010
Health Authority: United States: Federal Government

Keywords provided by National Institute of Environmental Health Sciences (NIEHS):
Parkinson Disease
Neurodegenerative

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases

ClinicalTrials.gov processed this record on April 15, 2014